Efficacy and safety of erlotinib in elderly patients with non-small-cell lung cancer harboring epidermal growth factor receptor mutations

Efficacy and safety of erlotinib in elderly patients with non-small-cell lung cancer harboring epidermal growth factor receptor mutations - Efficacy and safety of erlotinib in elderly patients with non-small-cell lung cancer harboring epidermal growth factor receptor mutations

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012056

Enrollment

Registered

2013-10-31

Start date

2013-10-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small-cell lung cancer

Interventions

Erlotinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically or cytologically confirmed non-small-cell lung cancer 2) Unresectable or postoperative recurrence NSCLC 3) EGFR mutation positive 4) Prior EGFR-TKIs is not accepted 5) ECOG PS 0-3 6) Measurable lesions (RECIST) 7) Age>=75years 8) Adequate function of main organ 9) Provided written informed consent

Exclusion criteria

Exclusion criteria: 1) EGFR mutation T790M positive 2) Active concomitant malignancy. 3) Interstitial pneumonia or pulmonary fibrosis on chest CT scans 4) Active concomitant malignancy 5) Pregnant or breast-feeding females 6) Inappropriate patients for this study judged by the physicians

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Secondary

Measure	Time frame
Time to Treatment Failure, Disease Control Rate, Overall survival, Response Rate, Quality of life	—

Countries

Japan

Contacts

Public ContactSutani Akihisa

Shimane university hospital Clinical oncology and Respiratory medicine

sutani@med.shimane-u.ac.jp0853-20-2580

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026